During the past decade, Henan Cancer Hospital conducted 466 clinical trials. In the 10-year time frame, 466 clinical trials started and 34 clinical trials were completed, i.e. on average, 7.3% percent of trials that started reached the finish line to date. In the past 5 years, 319 clinical trials started and 31 clinical trials were completed. i.e. 9.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Henan Cancer Hospital" #1 sponsor was "Henan Cancer Hospital" with 64 trials, followed by "BeiGene" with 35 trials sponsored, "Hoffmann-La Roche" with 27 trials sponsored, "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 23 trials sponsored and "Jiangsu HengRui Medicine Co., Ltd." with 23 trials sponsored. Other sponsors include 312 different institutions and companies that sponsored additional 168 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Henan Cancer Hospital" #1 collaborator was "LinkDoc Technology (Beijing) Co. Ltd." with 12 trials as a collaborator, "Henan Cancer Hospital" with 10 trials as a collaborator, "Jiangsu HengRui Medicine Co., Ltd." with 9 trials as a collaborator, "Eisai Inc." with 6 trials as a collaborator and "Cancer Institute and Hospital, Chinese Academy of Medical Sciences" with 5 trials as a collaborator. Other collaborators include 274 different institutions and companies that were collaborators in the rest 216 trials.

According to Clinical.Site data, the most researched conditions in "Henan Cancer Hospital" are "Breast Cancer" (27 trials), "Advanced Solid Tumor" (21 trials), "Gastric Cancer" (20 trials), "Multiple Myeloma" (15 trials) and "Non-small Cell Lung Cancer" (14 trials). Many other conditions were trialed in "Henan Cancer Hospital" in a lesser frequency.

Most popular intervention types in "Henan Cancer Hospital" are "Drug" (420 trials), "Biological" (37 trials), "Other" (22 trials), "Procedure" (16 trials) and "Combination Product" (7 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (49 trials), "Tislelizumab" (20 trials), "Cisplatin" (18 trials), "Carboplatin" (16 trials) and "Atezolizumab" (14 trials). Other intervention names were less common.

The vast majority of trials in "Henan Cancer Hospital" are 421 trials for "All" genders, 47 trials for "Female" genders and 13 trials for "Male" genders.

Currently, there are 317 active trials in "Henan Cancer Hospital". 20 are not yet recruiting, 200 are recruiting, 94 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 69 completed trials in Henan Cancer Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Henan Cancer Hospital, 115 "Phase 1" clinical trials were conducted, 192 "Phase 2" clinical trials and 169 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 10 trials that are defined as “Not Applicable".